entertainment -WSS

entertainment

author：knowledge 2025-10-02 06:02:26 - browse：4

A purple number 3 with an eye is surrounded by smaller, black number 3s on a green background — 3 to watch coverage from STAT — Christine Kao/STAT

Every winter, like Punxsutawney nobles, biotech’s many thought leaders gather for the J.P. Morgan Healthcare Conference to pick apart the year that was and prognosticate about the one to come. The consensus, in good markets and bad, is almost always cautious optimism for boom times ahead, a prediction that in recent years has had groundhog-level accuracy.

But after two years of steady decline, 2024 might finally prove them right. Biotech is on the upswing, driven by the rise of some headline-grabbing medicines, the advance of cutting-edge technologies, and a few reminders that big drug companies are still willing to pay billions of dollars for small ones.

Here are three major themes that we expect to drive the news in 2024 and determine whether biotech’s comeback is a sustainable trend or an interest-rate phenomenon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： In utero gene editing: an explainer

hotspot

entertainment

WSS

Alabama IVF ruling threatens families facing fatal genetic disease

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Adam's Take: Intra

This gene therapy has record $4.25 million price. It's saved children.

U.K. officials, researchers try to ease path for bespoke genetic treatments

'Patient friction coefficient' can gauge a clinical trial's patient burden

explore

entertainment

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

Chinese researcher claims birth of first gene

Tori Bowie and the unacceptable rates of Black maternal death

Alabama hospital puts IVF treatments on hold

Medical records are filled with copy

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Peter Hotez and the public health issue of online harassment

With Wegovy coverage, Medicare patients may face high costs

Moonlake's readout produced a cash windfall. Risks remain

Adam's Take: Intra

knowledge

Texas board proposes rules on abortion law emergency exemption

Mirador, a new biotech startup, launches with $400 million

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Medicare Advantage insurers pressure Biden for bigger payments

A new nitrogen execution bill also undermines medical licensing

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

hotspot

entertainment

focus

focus